key: cord-0804520-hku4pkpl
authors: Takumida, Hiroshi; Izumi, Shinyu; Sakamoto, Keita; Hashimoto, Masao; Ishii, Satoru; Suzuki, Manabu; Takasaki, Jin; Tanaka, Mariko; Igari, Toru; Hojo, Masayuki
title: Sustained coronavirus disease 2019-related organizing pneumonia successfully treated with corticosteroid
date: 2021-01-21
journal: Respir Investig
DOI: 10.1016/j.resinv.2020.12.005
sha: 639a7eb79a6339861f9c50b1711962e55f6c20fe
doc_id: 804520
cord_uid: hku4pkpl

A 70-year-old Japanese man contracted severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and required oxygen to maintain oxygen saturation (>90%), 5 weeks after onset of coronavirus disease 2019 (COVID-19) symptoms. Transbronchial lung cryobiopsy revealed pathological features of organizing pneumonia with alveolar epithelial injury, and prednisolone administration led to alleviation of respiratory symptoms and recovery of respiratory function. This case report is the first to demonstrate the use of corticosteroids to successfully treat post-COVID-19 respiratory failure in a patient with biopsy-proven organizing pneumonia. We propose that steroid treatment be considered for patients with persistent respiratory dysfunction as COVID-19 pneumonia sequelae.

cryobiopsy revealed pathological features of organizing pneumonia with alveolar epithelial 5 injury, and prednisolone administration led to alleviation of respiratory symptoms and 6 recovery of respiratory function. This case report is the first to demonstrate the use of 7 corticosteroids to successfully treat post-COVID-19 respiratory failure in a patient with 8 biopsy-proven organizing pneumonia. We propose that steroid treatment be considered for 9 patients with persistent respiratory dysfunction as COVID-19 pneumonia sequelae. (Fig. 1A, B ). Due to his severe respiratory status, he required high-flow 2 nasal cannula (fraction of inspiratory oxygen 0.65, oxygen flow rate 50 L/min) and was 3 administered antiviral drug (favipiravir) from days 1 to 4, which was discontinued due to liver 4 dysfunction. Methylprednisolone, 70 mg (1 mg/kg/day), was also administered for 5 days for 5 its expected anti-inflammatory effect. 6 Although his respiratory status improved, his need for supplemental oxygen persisted, with 4 7 L/min required to maintain oxygen saturation (>90%) (Fig. 2) . Also, CRP level remained Microscopically, OP with alveolar epithelial injury was noted. Fibrosis was focally embedded 21 in a myxoid matrix, predominantly involving the alveolar spaces and alveolar ducts. In the 22 central part of the fibrosis, the elastic fibers in the alveoli were destroyed. 23 Lymphoplasmacytic infiltration and scattered alveolar macrophages were observed within the 24 airspaces. Neither vasculitis nor capillaritis was observed (Fig. 3A, 3B) . Immunostaining of 25 J o u r n a l P r e -p r o o f the specimen did not detect SARS-CoV-2 nucleoprotein. 1 We administered oral prednisolone 70 mg (1 mg/kg/day) starting on day 31 and gradually 2 tapered over 4 weeks (Fig. 2) . His need for supplemental oxygen at rest, previously 4 L/min, 3 disappeared after 2 weeks of steroid therapy. Three weeks later, he did not need supplemental 4 oxygen, even on exertion. Findings on chest CT scans improved over time. Some 5 ground-glass opacities remained around previous consolidation, but almost all volume 6 reduction improved, and extensive infiltrative shadows disappeared (Fig. 1D) . Serum KL-6 7 normalized, and SP-D decreased to 121.3 ng/mL. He was discharged home on day 56, and 8 respiratory dysfunction has not relapsed as of this writing 3 months later. 

To our knowledge, this is the first report of a case in which steroid therapy was used to 12 successfully treat respiratory failure after COVID-19 in a patient with biopsy-proven OP. 13 Several reports exists on pathological features of patients with COVID-19. Pogatchinik et al. 14 [3] reported a correlation between lung consolidation and OP in the acute phase. Copin et al. 15 [4] reported organizing diffuse alveolar damage (DAD) patterns in the lungs of autopsy cases. 16 The pathology in our case showed OP with alveolar epithelial injury, suggesting severe local 17 inflammation. This finding may be related to the fact that SARS-CoV-2 targets 18 angiotensin-converting enzyme 2 receptor, which is expressed on the surface of type II 19 alveolar epithelial cells [5] . We did not find viral nucleoprotein in the lung tissue, which 20 suggests that the inflammation was caused not by persistent infection but by an ongoing 21 immune response. Hence, steroid treatment may have been useful. 22 The optimal timing of restarting steroid therapy in the late phase of COVID-19 remains a 23 challenge. We currently believe that it is better to reintroduce steroid therapy if improvement 24 of respiratory status is not sufficient or imaging findings worsen, for example, showing 25 J o u r n a l P r e -p r o o f 7 enlargement of shadows or shrinkage of the lung volume even after initial steroid therapy. The 1 number of patients with COVID-19 continues to increase, and there is now a growing 2 problem that many survivors may have persistent dyspnea and respiratory failure as sequelae 3 [2]. These patients who complain of dyspnea are often treated with only respiratory 4 rehabilitation and home oxygen therapy. This case report suggests that consolidation with 5 volume reduction in the lungs of patients with persistent respiratory symptoms after recovery 6 from COVID-19 is consistent with OP and that steroid therapy could be useful for treating the 7 sequelae. We propose that steroid treatment be considered for patients with post-COVID-19 8 pneumonia who have persistent respiratory dysfunction. 9 10 J o u r n a l P r e -p r o o f Acknowledgements 1 We are grateful to Drs. Noriko Nakajima and Tadaki Suzuki for helpful discussions of 2 immunostaining of SARS-CoV-2 nucleoprotein. We thank Dr. Tamiko Takemura for very 3 useful advice and comments on histological appearance. 

Abnormal pulmonary function in 2 COVID-19 patients at time of hospital discharge

for the Gemelli Against COVID-19 Post-Acute Care Study

Persistent symptoms in patients after acute COVID-19

The Japanese Respiratory Society All authors are required to disclose any COI within 3 calendar years preceding the current year, prior to the submission of any manuscript in the subject matter of which any company, entity, or organization has an interest.

No If Yes: List the name(s) of authors and commercial entity(ies) and use as much space as necessary This statement will be kept for 2 years after the publication of the manuscript.